FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002817467> ?p ?o ?g. }

• W2002817467 endingPage "602" @default.
• W2002817467 startingPage "595" @default.
• W2002817467 abstract "A prospective randomized controlled multicenter phase III trial was conducted to evaluate the effects of neoadjuvant chemotherapy with nimustine (ACNU)-cisplatin (CDDP) when used in conjunction with radiotherapy plus adjuvant temozolomide in patients with newly diagnosed glioblastoma. The study population was randomly assigned into one treatment and one control group. Both groups received radiotherapy followed by six cycles of adjuvant oral temozolomide (150-200 mg/m(2)) for 5 days every 28 days after surgery. Prior to radiotherapy, the treatment group also received two cycles, 6 weeks apart, of neoadjuvant chemotherapy with ACNU (40 mg/m(2)/day) and CDDP (40 mg/m(2)/day) infused continuously for 72 h. The primary end-point was median survival time. The study has closed after interim analysis with a total of 82 patients (48.8% of target number) due to unacceptable high frequency of toxicity profiles in spite of the promising actuarial survival outcome. Median survival time was 28.4 months [90% confidence interval (CI), 21.1 months to not available] in the treatment group and 18.9 months (90% CI, 17.1-27.4 months) in the control group (P = 0.2). The 2-year survival rate and progression-free survival time were 50.9% and 6.6 months (90% CI, 3.5-9.5 months) in the treatment group and 27.8% and 5.1 months (90% CI, 3.8-8.8 months) in the control group. Grade 3 or 4 toxicity was documented in 26 (68.4%) patients in the treatment group, including three neutropenic fever and one death from sepsis, while grade 3 or 4 toxicity occurred in 6 patients (15.8%) in the control group. The high frequency of serious hematological toxicity with ACNU-CDDP neoadjuvant chemotherapy followed by radiotherapy and adjuvant temozolomide limits its usage as primary treatment for glioblastoma. Future studies should aim to identify a subpopulation at reduced risk for ACNU-CDDP toxicity so that the potential of this protocol can be realized." @default.
• W2002817467 created "2016-06-24" @default.
• W2002817467 creator A5007364197 @default.
• W2002817467 creator A5011721894 @default.
• W2002817467 creator A5012153148 @default.
• W2002817467 creator A5018301481 @default.
• W2002817467 creator A5019037704 @default.
• W2002817467 creator A5024891671 @default.
• W2002817467 creator A5027678674 @default.
• W2002817467 creator A5033093147 @default.
• W2002817467 creator A5034241809 @default.
• W2002817467 creator A5044075250 @default.
• W2002817467 creator A5049872669 @default.
• W2002817467 creator A5054187738 @default.
• W2002817467 creator A5058144503 @default.
• W2002817467 creator A5058521062 @default.
• W2002817467 creator A5066161983 @default.
• W2002817467 creator A5066744863 @default.
• W2002817467 creator A5069535557 @default.
• W2002817467 creator A5079052740 @default.
• W2002817467 creator A5079181340 @default.
• W2002817467 date "2010-11-04" @default.
• W2002817467 modified "2023-10-18" @default.
• W2002817467 title "Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial" @default.
• W2002817467 cites W1514193558 @default.
• W2002817467 cites W1980170616 @default.
• W2002817467 cites W2007343138 @default.
• W2002817467 cites W2012988772 @default.
• W2002817467 cites W2017425912 @default.
• W2002817467 cites W2023489093 @default.
• W2002817467 cites W2028175681 @default.
• W2002817467 cites W2050771499 @default.
• W2002817467 cites W2096287682 @default.
• W2002817467 cites W2123133319 @default.
• W2002817467 cites W2133198620 @default.
• W2002817467 cites W2139008103 @default.
• W2002817467 cites W2142412446 @default.
• W2002817467 cites W2168656682 @default.
• W2002817467 cites W2270051382 @default.
• W2002817467 cites W2400892281 @default.
• W2002817467 cites W250690202 @default.
• W2002817467 doi "https://doi.org/10.1007/s11060-010-0427-y" @default.
• W2002817467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21052775" @default.
• W2002817467 hasPublicationYear "2010" @default.
• W2002817467 type Work @default.
• W2002817467 sameAs 2002817467 @default.
• W2002817467 citedByCount "29" @default.
• W2002817467 countsByYear W20028174672012 @default.
• W2002817467 countsByYear W20028174672013 @default.
• W2002817467 countsByYear W20028174672014 @default.
• W2002817467 countsByYear W20028174672015 @default.
• W2002817467 countsByYear W20028174672016 @default.
• W2002817467 countsByYear W20028174672017 @default.
• W2002817467 countsByYear W20028174672018 @default.
• W2002817467 countsByYear W20028174672019 @default.
• W2002817467 countsByYear W20028174672020 @default.
• W2002817467 countsByYear W20028174672021 @default.
• W2002817467 countsByYear W20028174672023 @default.
• W2002817467 crossrefType "journal-article" @default.
• W2002817467 hasAuthorship W2002817467A5007364197 @default.
• W2002817467 hasAuthorship W2002817467A5011721894 @default.
• W2002817467 hasAuthorship W2002817467A5012153148 @default.
• W2002817467 hasAuthorship W2002817467A5018301481 @default.
• W2002817467 hasAuthorship W2002817467A5019037704 @default.
• W2002817467 hasAuthorship W2002817467A5024891671 @default.
• W2002817467 hasAuthorship W2002817467A5027678674 @default.
• W2002817467 hasAuthorship W2002817467A5033093147 @default.
• W2002817467 hasAuthorship W2002817467A5034241809 @default.
• W2002817467 hasAuthorship W2002817467A5044075250 @default.
• W2002817467 hasAuthorship W2002817467A5049872669 @default.
• W2002817467 hasAuthorship W2002817467A5054187738 @default.
• W2002817467 hasAuthorship W2002817467A5058144503 @default.
• W2002817467 hasAuthorship W2002817467A5058521062 @default.
• W2002817467 hasAuthorship W2002817467A5066161983 @default.
• W2002817467 hasAuthorship W2002817467A5066744863 @default.
• W2002817467 hasAuthorship W2002817467A5069535557 @default.
• W2002817467 hasAuthorship W2002817467A5079052740 @default.
• W2002817467 hasAuthorship W2002817467A5079181340 @default.
• W2002817467 hasBestOaLocation W20028174672 @default.
• W2002817467 hasConcept C126322002 @default.
• W2002817467 hasConcept C141071460 @default.
• W2002817467 hasConcept C168563851 @default.
• W2002817467 hasConcept C203092338 @default.
• W2002817467 hasConcept C2775965419 @default.
• W2002817467 hasConcept C2776694085 @default.
• W2002817467 hasConcept C2777389519 @default.
• W2002817467 hasConcept C2908647359 @default.
• W2002817467 hasConcept C2992435398 @default.
• W2002817467 hasConcept C31760486 @default.
• W2002817467 hasConcept C509974204 @default.
• W2002817467 hasConcept C61943457 @default.
• W2002817467 hasConcept C71924100 @default.
• W2002817467 hasConcept C99454951 @default.
• W2002817467 hasConceptScore W2002817467C126322002 @default.
• W2002817467 hasConceptScore W2002817467C141071460 @default.
• W2002817467 hasConceptScore W2002817467C168563851 @default.
• W2002817467 hasConceptScore W2002817467C203092338 @default.
• W2002817467 hasConceptScore W2002817467C2775965419 @default.

• next